Avidity Biosciences (NASDAQ: RNA) CLO sell-to-cover RSU tax sale shares

Rhea-AI Filing Summary

Avidity Biosciences, Inc. Chief Legal Officer John B. Moriarty reported an automatic sale of common stock tied to restricted stock unit (RSU) vesting. On January 7, 2026, 2,374 shares of common stock were sold at $72.23 per share to cover tax withholding obligations from RSUs that vested on January 6, 2026, under a required “sell-to-cover” arrangement in the company’s equity incentive plans. This was not a discretionary trade and was executed under an instruction letter intended to satisfy the affirmative defense conditions of Rule 10b5-1. After this transaction, Moriarty beneficially owned 74,557 shares of Avidity Biosciences common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moriarty John B

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

3020 CALLAN ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S		2,374(1)	D	$72.23	74,557	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Remarks:

	/s/ Michael F. MacLean, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Avidity Biosciences (RNA) report?

Avidity Biosciences reported that its Chief Legal Officer, John B. Moriarty, sold 2,374 shares of common stock on January 7, 2026 in a Form 4 filing.

At what price were the Avidity Biosciences (RNA) shares sold in this Form 4?

The reported transaction shows a sale of Avidity Biosciences common stock at a price of $72.23 per share for the 2,374 shares sold.

Why did Avidity Biosciences CLO John B. Moriarty sell shares?

The 2,374 shares were sold to cover tax withholding obligations arising from the vesting of RSUs on January 6, 2026, under a mandated “sell-to-cover” arrangement.

Was the Avidity Biosciences insider sale a discretionary trade?

No. The filing states the sale was mandated by the issuer under its equity incentive plans as a required “sell-to-cover” transaction and does not represent a discretionary trade by the reporting person.

Is the Avidity Biosciences (RNA) Form 4 transaction under a Rule 10b5-1 plan?

Yes. The reporting person executed an instruction letter for automatic “sell-to-cover” sales that is intended to satisfy the affirmative defense conditions of Rule 10b5-1.

How many Avidity Biosciences shares does the CLO hold after this transaction?

Following the sale, John B. Moriarty beneficially owned 74,557 shares of Avidity Biosciences common stock directly.

What is the role of the reporting person in Avidity Biosciences (RNA)?

The reporting person, John B. Moriarty, is identified as the company’s Chief Legal Officer in the Form 4 filing.